Invicta Diagnostic (NSE:INVICTA) Notes Receivable: ₹0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INVICTA Invicta Diagnostic Ltd NSE:INVICTA
22 GF Score
Price ₹69.65
! 3 Warning Signs
View Full Analysis

What is Invicta Diagnostic Notes Receivable?

Invicta Diagnostic NSE:INVICTA +3.88% 22 Notes Receivable is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Invicta Diagnostic's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0.0 Mil.

Invicta Diagnostic Notes Receivable Related Terms

Invicta Diagnostic Notes Receivable Historical Data

* Premium members only.

The historical data trend for Invicta Diagnostic's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invicta Diagnostic Notes Receivable Chart

Invicta Diagnostic Annual Data
Trend Mar24 Mar25 Mar26
Notes Receivable
0.00 0.00 0.00

Invicta Diagnostic Semi-Annual Data
Mar24 Mar25 Sep25 Mar26
Notes Receivable 0.00 0.00 0.00 0.00
NSE:INVICTA
22GF Score
Invicta Diagnostic Ltd NSE:INVICTA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invicta Diagnostic Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0.0 Mil mean?
Invicta Diagnostic (NSE:INVICTA) has a Notes Receivable of ₹0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Invicta Diagnostic and its competitors.
Is Invicta Diagnostic's Notes Receivable too high?
Invicta Diagnostic's current Notes Receivable is ₹0.0 Mil. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's Notes Receivable compare to TMO and DHR?
Invicta Diagnostic's Notes Receivable of ₹0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Invicta Diagnostic and its competitors. Invicta Diagnostic's current Notes Receivable is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current Notes Receivable of ₹0.0 Mil. The current Notes Receivable is ₹0.0 Mil. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current Notes Receivable is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invicta Diagnostic Business Description

Address Western Express Highway, Office No. 1012, 10th Floor, Hubtown Viva CHS Ltd, Mogra Village, Near Shankarwadi, Jogeshwari East, Mumbai, MH, IND, 400 060
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score

Get the complete analysis for NSE:INVICTA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹69.65
Price